Floatz logo

Taselisib

Rectal Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
89/ 100

Competitive context

113 Active assets in the Rectal Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

Taselisib is also rated in:

breast carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →